Welcome to the Working Group on New TB Drugs Blog
Posted in Front Lines of TB R&D, TB Drug Development, TB R&D Spotlight Interviews, TB Treatment, Voices from the Fight to Stop Tuberculosis, WGND Podcast Series
TB R&D Weekly Update: Podcast Interview with Dr. Edward Nardell
This week, we feature an interview with Dr. Edward Nardell who is a pulmonologist with a special interest in tuberculosis. His principal academic appointment is as associate professor of medicine, Harvard Medical School. In 2002 he joined Partners In Health as Director of Tuberculosis Research. During the interview, we discuss with Dr. Nardell his background and interest in TB, the Airbourne Infections Research (AIR) Facility, his thoughts on the MDR-TB epidemic, and his current research focus. Additional links to TB R&D News are included.
Posted in Front Lines of TB R&D, TB Drug Development, TB R&D Spotlight Interviews, WGND Podcast Series
TB R&D Weekly Update: Podcast Interview with Eric Nuermberger
In this week”s TB R&D update, the WGND had the opportunity to talk with Dr. Nuermberger on a recent article entitled “PA-824 exhibits time-dependent activity in a murine model of tuberculosis” that we covered in a previous TB R&D Weekly Update. In the interview, Dr. Nuermberger provides an overview of his present research, key results presented in the article, and in vitro and preclinical testing of TB drug regimens. Also, links to additional news in TB R&D are included.
Posted in Front Lines of TB R&D, TB R&D Spotlight Interviews, TB Treatment, WGND Podcast Series
TB R&D Weekly Update: Podcast Interview with Peter Andersen
In this week”s TB R&D update, The WGND had the opportunity to talk with Dr. Andersen on a recent article entitled “A multistage tuberculosis vaccine that confers efficient protection before and after exposure” that we covered in a previous TB R&D Weekly Update. In the interview, Dr. Andersen provides an overview of his present research and the article, possible integration of a vaccine that protects pre- and post- exposure into TB treatment, and the challenges for TB vaccine development. Also, links to additional news in TB R&D are included.
TB R&D Weekly Update: Podcast Interview with Philip Bourne
In this week”s TB R&D update, The WGND had the opportunity to talk with Dr. Bourne on a recent article published in PLoS Computational Biology in November 2010. Dr. Philip Bourne is a professor at University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences and Editor in Chief of PL0S Computational Biology. In the interview, Dr. Bourne discusses his present research, use of structural bioinformatics to inform drug discovery, and the need for open access in research. Also, links to additional news in TB R&D are included.
Posted in Front Lines of TB R&D, TB Drug Development, TB R&D Spotlight Interviews, WGND Podcast Series
TB R&D Weekly Update: Podcast Interview with Anne Lenaerts
In this week”s TB R&D update, the WGND had the opportunity to talk with Dr. Lenaerts on a recent article published ahead of print in the Antimicrobial Agents and Chemotherapy journal in December 2010. Dr. Anne Lenaerts is an associate professor at Colorado State University”s College of Veterinary Medicine and Biomedical Sciences in the Department of Microbiology, Immunology and Pathology. In the interview, Dr. Lenaerts provides an overview of her present research and the article, key recommendations for use of mouse models for testing TB drugs and the issue of relapse studies. Also, links to additional news in TB R&D are included.
Dr. Michele Miller on TB in Wildlife – Part Three of Three
TB R&D Spotlight Interview with Dr. Michele Miller: In part three of our talk with Dr. Michele Miller, the Chief Veterinary Officer and Director of the Center for Conservation Medicine at the Palm Beach Zoo, an expert on tuberculosis in wildlife populations, we discuss the state of funding to stop TB in wild animals.
Spotlight: Dr. Michele Miller on TB in Wildlife – Part Two
TB R&D Spotlight Interview with Dr. Michele Miller: In part two of our interview, we discuss the impact that TB could have on wildlife populations. Tuberculosis is currently a leading infectious disease in both human and animal populations across the world. Because it is an older disease, it goes under recognized in all groups – especially wildlife. While it may not generate as much attention as HIV, or Ebola, it can have greater impact on the balance of the environment and our wildlife populations.
Spotlight: Dr. Michele Miller on TB in Wildlife – Part One
TB R&D Spotlight Interview with Dr. Michele Miller: When we think of infectious diseases, such as HIV or Tuberculosis, we usually consider them to be a human problem – there are rarely reports of disease in animals, unless it impacts people directly. The reality, however, is that infection greatly impacts domestic and wild animals, greatly affecting the health of our environment.
-
You are currently browsing the archives for the TB R&D Spotlight Interviews category.
-
Toppix TB News- Editorial: Lives at risk if the U.S. shortchanges Global Fund 4 Feb 2012
- Multidrug-Resistant Tuberculosis - Update 3 Feb 2012
- Multidrug-Resistant Tuberculosis - Update 3 Feb 2012
- WHO says TB in Russia displays highest known drug resistance 3 Feb 2012
- Media outlets examine Global Fund's future as it enters second decade 3 Feb 2012
